

Tchaikapharma High Quality Medicines Inc.
Consolidated Statement of financial position
as of 31 March 2022

	31.03.2022	31.12.2021
Non-current assets	BGN'000	BGN'000
Property, plant and equipment	36,945	38,071
Intangible Assets and Goodwill	3,893	3,451
Trade receivables	5,276	5,276
Non-current assets	46,114	46,798
Inventories	8,616	11,342
Trade and other receivables	62,164	59,220
Current tax assets	40	40
Cash and cash equivalents	65	57
Current Assets	70,885	70,659
Assets	116,999	117,457
Issued capital	84,500	84,500
Statutory reserve	12,382	12,382
Retained earnings	3,814	1,937
Equity	100,696	98,819
<i>Equity Attributable to owners of the parent company</i>	<i>100,696</i>	<i>98,819</i>
<i>Non-controlling interest in equity</i>	<i>-</i>	<i>-</i>
Long term borrowings	1,609	1,717
Deferred tax liabilities	1,030	1,030
Non-current provisions for employee benefits	151	151
Non-current liabilities	2,790	2,898
Trade and other payables	2,156	4,721
Short term borrowings	10,708	10,771
Current tax liabilities	125	125
Current payables on Social Security and taxes	524	123
Current liabilities	13,513	15,740
Liabilities	16,303	18,638
Equity and liabilities	116,999	117,457

Date of preparation: 17.05.2022

Executive director:

Biser Georgiev

Prepared by:

Petya Moneva

Tchaikapharma High Quality Medicines Inc.
Consolidated statement of comprehensive income
as 31 March 2022


	31.03.2022	31.03.2021
	BGN'000	BGN'000
Revenue	12,778	13,386
Other income	54	2
Total income	12,832	13,388
Carrying amount of goods sold	(102)	(147)
Changes in inventories of finished products and work in progress	(560)	332
Materials and services	(7,735)	(7,787)
Personnel expenses	(1,371)	(1,345)
Depreciation / amortisation expenses	(940)	(1,072)
Other expenses	(73)	(199)
Finance income	5	1
Finance costs	(89)	(103)
Total expenses	(10,865)	(10,320)
Profit Loss before tax	1,967	3,068
Current tax expense income	(90)	(14)
Profit Loss	1,877	3,054
<i>Profit Loss attributable to owners of the parent company</i>	<i>1,877</i>	<i>3,054</i>
<i>Profit Loss attributable to non-controlling interests</i>	<i>-</i>	<i>-</i>
Other comprehensive income	1,877	3,054
<i>Profit Loss attributable to owners of the parent company</i>		
<i>Profit Loss attributable to non-controlling interests</i>		
Comprehensive income	1,877	3,054
<i>Profit Loss attributable to owners of the parent company</i>	<i>1,877</i>	<i>3,054</i>
<i>Profit Loss attributable to non-controlling interests</i>	<i>-</i>	<i>-</i>
Earnings per share / in BGN per 1 share /	0.02	0.04

Date of preparation: 17.05.2022

Executive director:


Biser Georgiev

Prepared by:


Petya Moneva

Tchaikapharma High Quality Medicines Inc.
Consolidated Cash flow statement
as of 31 March 2022

	31.03.2022	31.03.2021
	BGN'000	BGN'000
Cash flows from operating activities		
Receipts from sales of goods and rendering of services	7,570	8,344
Payments to suppliers for goods and services	(4,498)	(5,954)
Payments to and on behalf of employees	(1,343)	(1,319)
Effect of exchange rate changes on cash and cash equivalents	(12)	(4)
Income taxes paid classified as operating activities	(90)	
Other cash payments from operating activities	(1,079)	(495)
Cash flows from used in operating activities	548	572
 Cash flows from investing activities		
Purchase of other longterm assets classified as investing activities	(361)	(540)
Cash flows from used in investing activities	(361)	(540)
 Cash flows from financial activities		
Dividends paid classified as financing activities	49	33
Proceeds from borrowings classified as financing activities	(49)	(33)
Repayments of borrowings classified as financing activities	(49)	(50)
Payments of lease liabilities classified as financing activities	(130)	
Other inflows of cash classified as financing activities		1
Cash flows from used in financial activities	(179)	(49)
 Increase/Decrease in cash and cash equivalents	8	(17)
Cash and cash equivalents	57	64
Cash and cash equivalents	65	47

Date of preparation: 17.05.2022

Executive director:


Biser Georgiev

Prepared by:


Petya Moneva

Tchaikapharma High Quality Medicines Inc.
Consolidated statement on changes in equity
as of 31 March 2022

	Issued capital	Property plant and equipment revaluation surplus	Other reserves	Retained earnings	Equity abstract	Equity Attributable to owners of the parent company	Non- controlling interest in equity
	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>
Balance as of 01.01.2021	82,200	4,088	7,944	2,904	97,136	97,136	-
Profit Loss	-	-	-	1,396	1,396	1,396	-
Other comprehensive income	-	287	-	-	287	287	-
Comprehensive income	-	287	-	1,396	1,683	1,683	-
Increase/Decrease through appropriation of retained earnings	2,300	-	63	(2,363)	-	-	-
Total income expense	2,300	-	63	(2,363)	-	-	-
Balance as of 31.12.2021	84,500	4,375	8,007	1,937	98,819	98,819	-
Balance as of 01.01.2022	84,500	4,375	8,007	1,937	98,819	98,819	-
Profit Loss	-	-	-	1,877	1,877	1,877	-
Other comprehensive income	-	-	-	-	-	-	-
Comprehensive income	-	-	-	1,877	1,877	1,877	-
Increase/Decrease through appropriation of retained earnings	-	-	-	-	-	-	-
Total income expense	-	-	-	-	-	-	-
Balance as of 31.03.2022	84,500	4,375	8,007	3,814	100,696	100,696	-


Date of preparation: 17.05.2022

Executive director:



Biser Georgiev

Prepared by:



Petya Moneva